These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 15248822

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial.
    Verheyen N, Fahrleitner-Pammer A, Pieske B, Meinitzer A, Belyavskiy E, Wetzel J, Gaksch M, Grübler MR, Catena C, Sechi LA, Van Ballegooijen AJ, Brandenburg VM, Scharnagl H, Perl S, Brussee H, März W, Pilz S, Tomaschitz A.
    J Hypertens; 2016 Sep; 34(9):1778-86. PubMed ID: 27379537
    [Abstract] [Full Text] [Related]

  • 4. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
    Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M.
    Am J Kidney Dis; 2004 Aug; 44(2):250-6. PubMed ID: 15264182
    [Abstract] [Full Text] [Related]

  • 5. Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function.
    Moosgaard B, Vestergaard P, Heickendorff L, Mosekilde L.
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):35-42. PubMed ID: 17201799
    [Abstract] [Full Text] [Related]

  • 6. Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation.
    Yamashita H, Yamazaki Y, Hasegawa H, Yamashita T, Fukumoto S, Shigematsu T, Kazama JJ, Fukagawa M, Noguchi S.
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4211-5. PubMed ID: 15827108
    [Abstract] [Full Text] [Related]

  • 7. Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism.
    Tebben PJ, Singh RJ, Clarke BL, Kumar R.
    Mayo Clin Proc; 2004 Dec; 79(12):1508-13. PubMed ID: 15595334
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
    Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB.
    Kidney Int; 2003 Dec; 64(6):2272-9. PubMed ID: 14633152
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Fibroblast Growth Factor-23 and Vitamin D Metabolism in Subjects with eGFR ≥60 ml/min/1.73 m².
    Nakatani S, Nakatani A, Tsugawa N, Yamada S, Mori K, Imanishi Y, Ishimura E, Okano T, Inaba M.
    Nephron; 2015 Dec; 130(2):119-26. PubMed ID: 26068724
    [Abstract] [Full Text] [Related]

  • 14. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.
    Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M.
    Am J Kidney Dis; 2004 Sep; 44(3):481-7. PubMed ID: 15332221
    [Abstract] [Full Text] [Related]

  • 15. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
    Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y.
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1268-76. PubMed ID: 20448073
    [Abstract] [Full Text] [Related]

  • 16. Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?
    Witteveen JE, van Lierop AH, Papapoulos SE, Hamdy NA.
    Eur J Endocrinol; 2012 Jan; 166(1):55-60. PubMed ID: 21984611
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Elevated serum parathyroid hormone concentration in eucalcemic patients after parathyroidectomy for primary hyperparathyroidism and its relationship to vitamin D profile.
    Dhillon KS, Cohan P, Darwin C, Van Herle A, Chopra IJ.
    Metabolism; 2004 Sep; 53(9):1101-6. PubMed ID: 15334367
    [Abstract] [Full Text] [Related]

  • 19. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K.
    Clin J Am Soc Nephrol; 2015 Jun 05; 10(6):1021-30. PubMed ID: 25873267
    [Abstract] [Full Text] [Related]

  • 20. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism.
    Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L.
    Clin Endocrinol (Oxf); 2005 Nov 05; 63(5):506-13. PubMed ID: 16268801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.